Investors

Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Events & Presentations
Corporate Presentation
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community
- New biomarker data from the open-label extension (OLE) of the Phase 2 OASIS trial for etrasimod in patients with moderately to severely active ulcerative colitis (UC) - Arena sponsored dinner symposium: HYPE, HOPE or REALITY? Integrating histology into a treat-to-target strategy in UC, with
Toggle Summary FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
- APD418 currently in Phase 1 clinical investigation - data expected this year SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation for APD418, a β 3 -adrenergic